Recruiting
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
NCT07781644· Phase 2· Hoffmann-La Roche· Source
Recruiting
A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2- NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
2026-525328-10-00· Phase 2· Medica Scientia Innovation Research S.L.· Source
Not yet recruiting
Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)
NCT07247786· Phase 2· Fundación GECP· Source
Not yet recruiting
A study that compares Depigoid Olea (a medication to treat olive pollen allergies) and placebo in patients who have a runny nose and pink and itchy eyes due to olive pollen allergy.
2026-525840-13-00· Phase 3· LETI Pharma S.L.U.· Source
Recruiting
A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.
2025-524488-18-00· Phase 2· Astellas Pharma Global Development Inc.· Source
Not yet recruiting
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.
2026-525883-17-00· Phase 3· Genmab A/S· Source
Recruiting
BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer
NCT07492641· Phase 3· BeOne Medicines I GmbH· Source
Not yet recruiting
A Study to Evaluate the Efficacy and Safety of CP-012B in Participants With Parkinson’s Disease With Early Morning OFF Episodes
2026-526634-46-00· Phase 2· Contera Pharma A/S· Source
Recruiting
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
2025-522818-23-00· Phase 3· Zai Lab (US) LLC· Source
Recruiting
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916· Phase 3· ViiV Healthcare· Source
Recruiting
Grass Immunotherapy for Rhinitis and Asthma (GIRA)
2025-521736-10-00· Phase 3· LETI Pharma S.L.U.· Source
Recruiting
Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES)
2025-521709-42-00· Phase 3· LETI Pharma S.L.U.· Source
Recruiting
Mindfulness-Based Cognitive Therapy (MBCT) for the Prevention of Depression Relapse or Recurrence Using Videoconference
NCT06832605· Fundació Sant Joan de Déu· Source
Contact: Jose M Rico, Doctor
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152· Phase 3· Immuneering Corporation· Source
Recruiting
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
NCT07242547· Phase 2· Fundación GECP· Source
Recruiting
Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)
NCT07611747· Phase 4· Instituto de Investigación Marqués de Valdecilla· Source
Recruiting
LONG NAGOMI™ PMCF STUDY
NCT07399002· Fundación EPIC· Source
Contact: TAMARA GARCIA CAMARERO, MD, PhD
Recruiting
Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy
NCT07461220· Phase 1/2· Integrative Research Laboratories AB· Source
Contact: PI Dr. Eric Freyre Alvarez
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546· Phase 2· ViiV Healthcare· Source
Recruiting
A Study in Adults with Parkinson's Disease and a Lack of Interest or Motivation to Test How Different Doses of IRL757 Given for Multiple Days are Tolerated in the Body
2025-523612-37-00· Phase 1· Integrative Research Laboratories Sweden AB· Source
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· Phase 3· Boehringer Ingelheim· Source
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
NCT07266831· Phase 2/3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Eli Lilly and Company· Source
Contact: Federico Jose Vazquez Mazon (principal investigator)
Recruiting
NOPE37: Angiogenic Factors for Managing Term Preeclampsia
NCT07193680· Hospital Universitari Vall d'Hebron Research Institute· Source
Contact: Claudia Rodriguez
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229· Phase 3· Bristol-Myers Squibb· Source
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310· Phase 3· Hoffmann-La Roche· Source
Recruiting
Phase III clinical trial to evaluate the efficacy and safety of specific immunotherapy with mannanconjugated allergoids for the treatment of rhinitis/rhinoconjunctivitis in patients allergic to house
dust mites.
2023-508548-23-00· Phase 3· Inmunotek S.L.· Source
Recruiting
Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis
NCT07465848· Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)· Source
Contact: Javier David Benítez, MD
Recruiting
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
NCT07197866· Phase 2· Teva Branded Pharmaceutical Products R&D LLC· Source
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
PALACE: Cemiplimab Trial According to ctDNA Levels
NCT06917573· Phase 2· Fundación GECP· Source
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· Phase 3· Pfizer· Source
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732· Phase 3· Bristol-Myers Squibb· Source
Recruiting
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer
2024-513122-27-00· Phase 3· Daiichi Sankyo Inc.· Source
Recruiting
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
NCT06976268· Phase 2/3· Biohaven Therapeutics Ltd.· Source
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531· Phase 3· Astellas Pharma Global Development, Inc.· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Study to evaluate efficacy and safety of inclisiran in children aged 6 to under 12 years of age with heterozygous familial hypercholesterolemia.
2024-514594-21-00· Phase 3· Novartis Pharma AG· Source
Active, not recruiting
Long Acting Cabotegravir plus Rilpivirine in People Living with HIV-1 (PLHIV) Aged ≥ 60 Years for 24 months.
2022-502882-53-00· Phase 4· Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia· Source
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· Phase 3· Daiichi Sankyo· Source
Recruiting
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
2022-502352-31-00· Phase 3· Amgen Inc.· Source
Recruiting
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
NCT06431633· Phase 3· Fundación GECP· Source
Active, not recruiting
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· Phase 3· Pfizer· Source
Active, not recruiting
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927· Phase 3· Arcus Biosciences, Inc.· Source
Recruiting
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
NCT06435429· Phase 3· Jazz Pharmaceuticals Ireland Limited· Source
Active, not recruiting
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
NCT06706622· Phase 3· H. Lundbeck A/S· Source
Showing 50 of 97.